<DOC>
	<DOCNO>NCT00780754</DOCNO>
	<brief_summary>Patients diagnosis HPIN enrol . Patients randomize two group : dutasteride treatment group watchful wait strategy group . According study protocol subject would undergo 10 core biopsy 6 , 12 , 24 , 36 month randomization . There assessed rate prostate cancer repeat transrectal ultrasound guide biopsy effect 5 alfa reductase inhibitor ( dutasteride ) prevention prostate cancer development patient high grade intraepithelial neoplasia ( HPIN ) .</brief_summary>
	<brief_title>Prevention Prostate Cancer With Dutasteride Case High Grade PIN Neoplasia</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>1 . Age 4080 year 2 . HPIN prostate biopsy specimens 3 . PSA 20ng/ml 4 . No hormone therapy radiation pelvic region 5 . No previous treatment 5alfa reductase inhibitor 6 . Signed Subject Information Informed Subject Consent Form . 1 . Not compensate cardiovascular , pulmonary , hepatic renal function , neurological , psychiatric disease , sepsis , etc .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>chemoprevention</keyword>
	<keyword>dutasteride</keyword>
</DOC>